cyrilzakka/clinical-trials huggingface dataset:
Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion

The aim of this work is to assess the effectiveness and safety of Ulipristal Acetate in the management of 2nd trimester missed abortion along with misoprostol in pregnant women with previous caesarean section versus the use of misoprostol only with placebo as regards the time needed for abortion,Hypothesis: In pregnant women with 2nd trimester missed abortion with previous caesarean section , Ulipristal Acetate may decrease the time interval to achieve abortion when combined with Misoprostol in comparison to misoprostol alone.the included women divided to 2 groups Group A: will receive Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017.Group B: will receive placebo then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. then we assess Induction-to-abortion interval time.


Eligibility Criteria:
Inclusion Criteria: • Women with 2nd trimester missed abortions

* Gestational age 13-26 weeks.
* Women with a previous caesarian section scar,(para 1cs till para 4 cs).
* Women counseled and chose medication abortion rather than surgical evacuation

Exclusion Criteria:

* Women with an accompanying medical disorder such as: Preeclampsia, Diabetes Mellitus or Heart disease.
* Primigravida women or non scarred uterus.
* Women with previous myomectomy or hysterotomy scar or upper segment caesarean section scar.
* Induction of abortion in women with congenital fetal malformations or positive fetal pulsations due to medical disorder.
* Women with placenta previa .
* Allergy or contraindications to either Ulipristal acetate or Misoprostol.
* Women with inevitable abortion in the form of vaginal bleeding or uterine contractions
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

The purpose of this study is to assess the mass balance (that is, cumulative excretion of total radioactivity \[TRA\] in urine and feces) and to characterize the pharmacokinetics (PK) of pevonedistat in whole blood, plasma, and urine, and of TRA in plasma and whole blood following a single 1-hour infusion of 25 milligram per square meter (mg/m\^2) \[14C\]-pevonedistat intravenous (IV) solution containing approximately 60 to 85 microcurie (mCi) (approximately 2.22-3.145 megabecquerel \[MBq\]) of TRA in participants with advanced solid tumors in Part A.

The drug being tested in this study is called Pevonedistat. Pevonedistat is being tested to treat people with advanced solid tumors.

The study will enroll approximately 4 to 6 pharmacokinetics (PK)-evaluable participants in part A. After completion of the mass balance and absorption, distribution, metabolism, excretion (ADME) assessment in Part A of the study, eligible participants will have the opportunity to continue into Part B at a secondary study site, which would begin in approximately 2 weeks of completion of Part A.

* \[14C\]-Pevonedistat 25 mg/m\^2
* Part B (optional): Pevonedistat in combination with chemotherapy regimens (Pevonedistat 25 mg/m\^2 + docetaxel 75 mg/m\^2 or pevonedistat 20 mg/m\^2 + carboplatin 20 mg/m\^2 + paclitaxel 175 mg/m\^2)

All participants will receive study drug via intravenous route. This multi-center trial will be conducted in Hungary. Participants will remain confined to the study site for 9 to 14 days in Part A. Participation in Part B is optional, participants will be re-evaluated for inclusion/exclusion criteria before administrating treatment. Participants will undergo treatment in Part B for a maximum of 12 cycles (21 days cycle each) and will include approximately 36 weeks for Part A and B combined. Participants will attend an end of study visit 30 days after the last dose of study drug in both Part A and B.

Eligibility Criteria:
Inclusion Criteria:

1. Have a histologically or cytologically confirmed metastatic or locally advanced and incurable solid tumor that is felt to be appropriate for treatment with one of the 2 chemotherapy regimens in Part B of this study (carboplatin+paclitaxel or docetaxel), or have progressed despite prior standard therapy, or for whom conventional therapy is not considered effective. The tumor must be radiographically or clinically evaluable and/or measurable.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
3. Expected survival longer than 3 months from enrollment in the study.
4. Recovered (that is, less than or equal to \[\<=\] Grade 1 toxicity) from the effects of prior antineoplastic therapy.

Exclusion Criteria:

1. Has irregular defecation patterns (less than 1 defecation per 2 days or excessive diarrhea) and/or has a history of changes in bowel habits with daily routine or environment changes.
2. Prior treatment with radiation therapy involving greater than or equal to (\>=) 25% of the hematopoietically active bone marrow.
Minimally Invasive Lateral Approach for Sinus Augmentation: a Split-mouth Randomized Clinical Trial.

It is assumed that the minimally invasive lateral approach and the traditional lateral sinus lift procedure will result in better outcomes in terms of height of augmented bone.

It is also assumed that the minimally invasive lateral approach will reduce surgical complications and patient's discomfort in comparison with a traditional lateral sinus lift procedure.

16 patients edentulous in maxillary posterior area will be treated with a bilateral sinus lift procedure.

Once a patient will be enrolled in the study impressions will be taken. After the wax-up, a radiographic stent will be prepared. Special attention will be given to position radio-opaque references in the positions where the implants will be inserted according to a prosthodontic guided insertion. Pre-surgical CT scan will be executed after placing the stent in its proper position in patient's mouth. After that, if no surgical contra-indications will be detected at CT evaluation, patients will be enrolled for surgical interventions.

Eligibility Criteria:
Inclusion Criteria:

* - patient edentulous in the maxillary posterior area on both left and right side( not completely edentulous).
* - residual bone height in the maxillary premolar and molar region less than 4mm.

Exclusion Criteria:

* - history of systemic diseases that would contraindicate surgical treatment
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after \[F-18\] HX4 injection. This study will provide guidance for future studies involving \[F-18\]HX4 in cancer patients.

Each consented patient will have a single administration of \[F-18\]HX4 and will immediately undergo one list mode PET/CT imaging session lasting 60 minutes followed by three additional list mode PET/CT acquisitions from 90 to 110 minutes, 150 to 170 minutes and 220 to 250 minutes after administration. The start times of the last three image acquisitions are permitted to be within ± 5 minutes. Venous blood samples will be collected throughout the initial scan sequence and at the time of each subsequent acquisition for calibration and metabolite-correction of the image-derived input function. On the day of administration (Visit 2) blood for clinical safety evaluations will be drawn pre- and post-dosing after all imaging is complete.

The pre-surgery \[F-18\]FDG PET/CT clinical scan performed prior to the \[F-18\]HX4 procedure, and the surgery at Visit 3 are standard of care for the consented patients.

Eligibility Criteria:
Inclusion Criteria:

* Patient is \>18 years and male or female of any race / ethnicity.
* Patient or patient's legally acceptable representative provides written inform consent Patient is willing and able to comply with protocol procedures.
* Patient has newly diagnosed histologically confirmed squamous cell carcinoma of the head and/or neck whose primary origin is from the oral cavity, oropharynx, hypopharynx, larynx or nasopharynx.
* Patient is scheduled to have or already has had a clinical \[F-18\]FDG PET/CT scan prior (recommended to be within 14 days prior) to the \[F-18\]HX4 PET/CT scan.
* Patient has a primary tumor ≥ 2.0 cm in longest axis measured by CT or MR; or lymph node ≥ 2.0 cm in shortest axis measured by CT or MR if primary tumor \< 2 cm on CT or MR; CT may be part of required \[F-18\]FDG PET/CT scan or a separate pre-surgery CT scan.
* Patient is scheduled to undergo complete tumor resection within 7 days for his/her cancer care after the \[F-18\]HX4 PET/CT scan is performed.
* Patient has not had nor will have neoadjuvant treatment, including radiation and chemotherapy, prior to patient's planned tumor resection.

Exclusion Criteria:

* Female patient is pregnant or nursing.
* Patient is not capable of remaining still for duration of imaging procedure (\~ 4 hours).
* Patient has undergone an investigative, radioactive research procedure within 7 days prior to study participation, or is scheduled to undergo such a procedure during the study participation period.
* Patient has chronic renal function failure or is on renal dialysis
* Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data.
Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis

Development of a new Patient Reported Outcome Measure (PROM) to assess patient's emotional wellbeing, and perceptions of Total Knee Replacement surgery for the treatment of knee arthritis.

Patients will complete the final developed questionnaire for quantitative analysis only (involves no administration of any medicinal products or medical devices) and is considered a low-risk project.

Patients will also be asked to complete the already validated EQ-5D-5L and Oxford Knee Score questionnaires at the same time as the final developed questionnaire following their Total Knee Replacement surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years of age or older.
* Patients who have undergone Total Knee Replacement surgery with a metal implant for the treatment of end-stage knee arthritis in the last 3 months.
* Patients who have only undergone one Total Knee Replacement surgery on the index knee.
* Patients who, in the opinion of the Investigator, are able to understand this project and co-operate with the requirements of participation.
* Patients who are able to give voluntary, written informed consent to participate in this project and from whom consent has been obtained.

Exclusion Criteria:

* Patients, who in the opinion of the Investigator, exhibit evidence of any condition or co-morbidity that would compromise their participation in the project.
* Patients who are unable to understand and communicate fluently in English.
* Patients who have experienced a complication following Total Knee Replacement surgery requiring a further hospital admission or revision surgery to the index knee.
Analysis of Pregnancy-Associated Plasma Protein-A and Interleukin-6 Gene Polymorphisms in Patients With Periodontitis

The aim of this study is to evaluate the relationship between pregnancy associated plasma protein-A (PAPP-A) and interleukin-6 (IL-6) gene polymorphisms and stage 3 grade B and C (S3GBC) periodontitis, and to compare periodontitis patients with healthy individuals.

A total of 226 systemically healthy subjects, consisted of 112 S3GBC periodontitis patients (P group) and 114 periodontally healthy individuals (H group) were included in our study. Clinical and demographic data were recorded. Genomic deoxyribonucleic acid (DNA) molecules were obtained from peripheral blood. Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes. The genotypic or allelic distributions of PAPP-A and IL-6 gene polymorphisms were similar between groups (p\>0.05). Our finding suggests that there is no relationship between PAPP-A and IL-6 gene polymorphismS and S3GBC periodontitis, furthermore no difference was detected between periodontitis patients and healthy individuals regarding this gene polymorphism.

Eligibility Criteria:
Inclusion Criteria:

Participants were eligible for inclusion if they were; systemically healthy non-smokers had not undergone periodontal treatment in the past 6 months had not used antibiotics or anti-inflammatory drugs in the preceding 3 months had not used any medication that could affect periodontal tissues in the past 6 months were 18 years of age or older were not pregnant, and were not lactating.

Exclusion Criteria:

The samples taken cannot be stored under appropriate conditions and are damaged.

The onset of a systemic disease in a systemically healthy individual.
Predicting the Lens Capsular Bag Size Using Pre-operative Biometry

Aim of this study is to assess whether a high-resolution scan of the crystalline lens before surgery may be helpful in predicting post-operative capsule bag diameter.

Most of the measurement procedures used in this study are non-invasive and all are used in standard routine clinical practice, the benefit/risk ratio appears acceptable.

However, a capsule tension ring will be used. A CTR is not used routinely, usually only in cataract operations in which the lens capsule is not stable enough - in other words, for stabilization. The insertion of the CTR is problem-free in most cases. In extremely rare cases, however, the lens capsule may be injured. And document complications will be collected, report them in a final paper. The CTR used in the study is a standard device and CE-marked device. Studies using CTR showed that it is beneficial in difficult cases.

Gonioscopy after cataract surgery will be performed after 1 week. At this time point the wound is already sealed and there appears to be no increased risk to the patient. In the first study performed in a similar fashion in 1999 gonioscopy was performed one day after surgery.

Aim of this study is to predict the diameter of the capsular bag using pre-operative optical biometry findings.

This is a prospective, observer-blind and monocentric study that includes patients scheduled for cataract surgery. Recruitment will take part on the day of pre-assessment. For each patient only one eye will be included.

In total 50 eyes of 50 patients will be included, of which at least 5 eyes with an axial eye length below 22.5mm and 5 eyes with an axial eye length above 25.0mm.

Eligibility Criteria:
Inclusion Criteria:

* Patient scheduled for cataract surgery
* Well dilated pupil at the pre-assessment visit (dilated pupil size at least 6.0mm)
* Age 21 and older
* Pre-operative visual acuity of at least 0.25 Snellen

Exclusion Criteria:

* Parameters that influence the capsular bag stability (pseudoexfoliation syndrome, St. p. severe eye trauma, Phakodonesis)
* In women of childbearing age, a pregnancy test will be performed before inclusion into the study.
Real-time Ultrasound Imaging as Feedback for Deep Cervical Extensors Activation

The aim of this study will be to determine the value of adding real-time ultrasound imaging (RUSI) as an external feedback tool for teaching the contraction of the deep cervical extensors (DCE) in healthy subjects. The potential benefit of RUSI to facilitate activation of the DCE during a specific motor task as well as the retention capacity of this motor task after a short period of training will be investigated

Participants will be randomly allocated into two exercise groups: "DCE exercise without RUSI feedback (DCE)" and "DCE exercise with RUSI feedback (DCE+RUSI)".

Participants assigned to DCE will perform an exercise known to selectively activate the semispinalis cervicis muscles. By the other hand, participants in the DCE+RUSI group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance. In both groups, a total of 10 sets of 10 repetitions will be performed with one minute of rest between each set.

Ultrasound measurement will be used to asses the antero-posterior dimension (thickness) of the DCE both at rest and during contraction at the level of C4 at baseline, immediately after the DCE exercise activation protocol and one-week follow-up in order to evaluate retention capacity.

All participants will be asked to not perform any other cervical motor control exercise or exercise using RUSI feedback until the last time point assessment will be finished.

All participants will be asked to avoid any exercises or treatments for neck pain between sessions.

All ultrasound images will be analysed off-line using Image J software. Thickness and percent thickness change will be measured. The percent thickness change will be calculated by using the following equation: thickness contracted - thickness rest / thickness rest.

Eligibility Criteria:
Inclusion Criteria:

* No actual neck pain
* Being able to understand Spanish language

Exclusion Criteria:

* Neck pain in the last 3 months
* Previous surgery in the neck region
* Neurological diseases or any other condition that may alter voluntary muscle contraction
* Previous experience with cervical motor control training exercises
* Previous experience using RUSI as an external feedback tool in any other body area
Database of Data Collection

For several years, the Paoli-Calmettes Institute has been centralizing the retrospective collection of clinical data of patients operated on for histologically proven breast cancer.

The current cohort (G3S) fed by more than 20 centers has more than 25,000 patient records. The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news. The current database is also updated regularly.

Eligibility Criteria:
Inclusion Criteria:

* patients operated for histologically proven breast cancer.

Exclusion Criteria:

* Patient below age of 18 years
The Effect of Virtual Reality and Distraction Cards on Pain

When the literature is examined, it is seen that virtual reality and distraction cards are used during medical procedures, and they have a reducing effect on pain perception and lowering the level of anxiety . On the other hand, no study has been found in the literature on the application of virtual glasses and distraction cards to women in the PAP-SMEAR process. However, in accordance with the results of the study conducted with the application of virtual reality glasses and distraction cards, it is thought that the application of virtual glasses will have a positive effect on reducing the perceived pain of women in the PAP-SMEAR process of distraction cards.

Cervical cancer is the fourth most common cancer worldwide. Cervical cancer is one of the most successfully treatable types of cancer, as long as it is detected early and managed effectively. WHO recommends the use of PAP-SMEAR and HPV DNA primary screening test to prevent cervical cancer in women. . The crude incidence of cervical cancer per 100,000 women in Turkey in 2020 is . WHO has targeted a threshold of 4 per 100,000 women by 2030 for countries to eliminate cervical cancer. To achieve this goal, 90% of girls should be vaccinated with HPV until the age of 15, and 70% of women should be screened with high performance PAP-SMEAR and HPV DNA at the age of 35 and 45 For this reason, it is seen that the PAP-SMEAR test has an important place in the protection of women's health. For the Pap-Smear test procedure, gynecological examination and speculum examination are included . Experiencing pain, anxiety, shyness and fear during gynecological examination are among the barriers to applying for and taking the pap-smear test, which has an important place in protecting women's health In the literature, it is seen that virtual reality glasses and distraction cards, which are cognitive behavioral techniques, are used during medical procedures and have a reducing effect on the perception of pain and reduce the level of anxiety . No study has been found that examines the effect on satisfaction and satisfaction levels. However, in line with the results of the study, it is thought that the PAP-SMEAR procedure will have a positive effect on women's perceived pain and anxiety, and increase their satisfaction levels. It emphasizes the need for cost-effective and feasible non-pharmacological methods by healthcare professionals during PAP-SMEAR application.

Eligibility Criteria:
Inclusion Criteria:

* 30-65 years old, To see menstruation on the day of the operation, Turkish literate, No history of cervical surgery No active mental illness Did not use any pain or anxiety medication prior to the insertion procedure

Exclusion Criteria:

* Those with visual and auditory disabilities, Using misoprostol during the procedure, Using pain medication before the procedure
Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis

The objective of this study is to determine if early parametric positron emission computed tomography is useful to diagnose cardiac prosthetic valve infections.

In addition to routine examinations (biological and microbiological tests, transesophageal or transthoracic ultrasound, transesophageal or transthoracic ultrasound, and leukocyte scintigraphy) of a parametric acquisition during the positron emission computed tomography parametric acquisition during positron emission computed tomography , this examination being itself planned in a standard way.

The definitive diagnosis according to the Duke-Li criteria will be established three months later in a multidisciplinary consultation meeting.

The final diagnosis according to the Duke-Li criteria will be made three months later in a multidisciplinary consultation meeting, blinded to the results of the parametric positron emission computed tomography, and with knowledge of the results of the standard positron emission computed tomography and the entire work-up.

Results and all the complementary work-up.

Eligibility Criteria:
Inclusion Criteria:

* Age superior to18 years,
* Effective contraception for women of childbearing age or negative pregnancy test on the day of the exam
* Good general condition. WHO ≤ 1
* Suspicion of endocarditis on a prosthetic heart valve implanted more than 3 months ago
* Labeled polynuclear scintigraphy performed within a maximum of 15 days before positron emission computed tomography
* Standard positron emission computed tomography planned as part of the extension assessment
* Informed and signed consent before any specific study procedure.
* Patient affiliated to the social security system

Exclusion Criteria:

* Presence of an active cancer in the previous three years
* Pregnancy or breastfeeding
* Poorly controlled diabetic patients
* Protected adults (under guardians or curators)
* Impossible decubitus (orthopnea, ...),
* Hypersensitivity to FDG or to one of the excipients of the radiopharmaceutical.